Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug rezetecan versus standard of care in platinum-resistant ovarian cancer
2025-523361-25-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Mocertatug rezetecan with Standard of care / physician's choice (2 arms). Primary endpoints: Progression-free survival by BICR and Overall survival. Planned start Sep 2026; status: authorised.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2025-523361-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523361-25-00.